{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:48:46Z","timestamp":1761821326067},"reference-count":16,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":794,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1002\/pbc.24646","type":"journal-article","created":{"date-parts":[[2013,6,29]],"date-time":"2013-06-29T13:59:22Z","timestamp":1372514362000},"page":"E163-E165","source":"Crossref","is-referenced-by-count":10,"title":["Ofatumumab for refractory opsoclonus-myoclonus syndrome following treatment of neuroblastoma"],"prefix":"10.1002","volume":"60","author":[{"given":"Tyler G.","family":"Ketterl","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Pediatrics; University of Minnesota; Minneapolis Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoav H.","family":"Messinger","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology-Children's Hospitals and Clinics of Minnesota; Minneapolis and St. Paul; Minneapolis Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn R.","family":"Niess","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology-Children's Hospitals and Clinics of Minnesota; Minneapolis and St. Paul; Minneapolis Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Gilles","sequence":"additional","affiliation":[{"name":"Pediatric Neurology-Children's Hospitals and Clinics of Minnesota; Minneapolis and St. Paul; Minneapolis Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William Keith","family":"Engel","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology; Northwest Eye Clinic; Minneapolis Minnesota"},{"name":"Department of Surgery; Children's Hospitals and Clinics of Minnesota, Minneapolis and St. Paul; Minneapolis Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna L.","family":"Perkins","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology-Children's Hospitals and Clinics of Minnesota; Minneapolis and St. Paul; Minneapolis Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,6,29]]},"reference":[{"key":"10.1002\/pbc.24646-BIB0001|pbc24646-cit-0001","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/adc.2010.204792","article-title":"Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome","volume":"97","author":"Brunklaus","year":"2012","journal-title":"Arch Dis Child"},{"key":"10.1002\/pbc.24646-BIB0002|pbc24646-cit-0002","doi-asserted-by":"publisher","first-page":"381","DOI":"10.10007\/s00401-011-0876-1","article-title":"Paraneoplastic encephalomyelopathies: Pathology and mechanisms","volume":"122","author":"McKeon","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1002\/pbc.24646-BIB0003|pbc24646-cit-0003","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpn.2008.04.012","article-title":"Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma","volume":"13","author":"Raffaghello","year":"2009","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1002\/pbc.24646-BIB0004|pbc24646-cit-0004","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1542\/peds.109.1.86","article-title":"Opsoclonus-ataxia caused by childhood neuroblastoma: Developmental and neurologic sequelae","volume":"109","author":"Mitchell","year":"2002","journal-title":"Pediatrics"},{"key":"10.1002\/pbc.24646-BIB0005|pbc24646-cit-0005","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/pbc.21807","article-title":"Paraneoplastic gastro-intestinal anti-Hu syndrome in neuroblastoma","volume":"52","author":"Drukker","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24646-BIB0006|pbc24646-cit-0006","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/jnnp.2010.224105","article-title":"Which antibody and which cancer in which paraneoplastic syndromes","volume":"10","author":"Gozzard","year":"2010","journal-title":"Pract Neurol"},{"key":"10.1002\/pbc.24646-BIB0007|pbc24646-cit-0007","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1542\/peds.2004-0845","article-title":"Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome","volume":"115","author":"Pranzatelli","year":"2005","journal-title":"Pediatrics"},{"key":"10.1002\/pbc.24646-BIB0008|pbc24646-cit-0008","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2007-01-070656","article-title":"Increased natural killer cell expression of CD16,augmented binding,ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V\/V,V\/F polymorphism","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood"},{"key":"10.1002\/pbc.24646-BIB0009|pbc24646-cit-0009","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4161\/mabs.1.4.8895","article-title":"Ofatumumab","volume":"1","author":"Zhang","year":"2009","journal-title":"MAbs"},{"key":"10.1002\/pbc.24646-BIB0010|pbc24646-cit-0010","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2010.27.9836","article-title":"Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies","volume":"28","author":"Cheson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24646-BIB0011|pbc24646-cit-0011","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/pbc.23187","article-title":"Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus","volume":"58","author":"Pranzatelli","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24646-BIB0012|pbc24646-cit-0012","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1212\/01.WNL.0000144340.03364.BF","article-title":"Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes","volume":"63","author":"Llad\u00f3","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/pbc.24646-BIB0013|pbc24646-cit-0013","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00043426-200007000-00007","article-title":"Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus","volume":"22","author":"Antunes","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1002\/pbc.24646-BIB0014|pbc24646-cit-0014","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.24646-BIB0015|pbc24646-cit-0015","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"10.1002\/pbc.24646-BIB0016|pbc24646-cit-0016","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0029-1237723","article-title":"Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome","volume":"40","author":"De Grandis","year":"2009","journal-title":"Neuropediatrics"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24646","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24646","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.24646\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T20:37:17Z","timestamp":1645907837000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24646"}},"subtitle":["Ofatumumab for Refractory OMS"],"short-title":[],"issued":{"date-parts":[[2013,6,29]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.24646","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6,29]]}}}